Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: GLM007
MIFTS: 61

Glomerulonephritis

Categories: Blood diseases, Immune diseases, Nephrological diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Glomerulonephritis

About this section

MalaCards integrated aliases for Glomerulonephritis:

Name: Glomerulonephritis 39 12 77 54 56 6 45 15 74
Bright's Disease 54

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Nephrological diseases Immune diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:2921
MeSH 45 D005921
NCIt 51 C26784
SNOMED-CT 69 36171008
ICD10 34 N05 N08
UMLS 74 C0017658
Sources

Summaries for Glomerulonephritis

About this section
NIH Rare Diseases : 54 Glomerulonephritis is a type of kidney disease in which there is inflammation of the glomeruli, the tiny filters that remove excess waste and fluids from the blood. It may be acute or chronic (coming on gradually), and may occur on its own (primary) or be caused by another condition (secondary). Signs and symptoms may depend on the type and cause of the condition and may include blood in the urine; foamy urine; swelling of the face, eyes, or other body parts; abdominal pain; high blood pressure; fatigue; and/or other symptoms. If the condition is severe or prolonged, the kidneys can become damaged. It may be caused by a variety of infections and diseases, and sometimes the cause is unknown. Treatment depends on the cause, type and severity of the condition.

MalaCards based summary : Glomerulonephritis, also known as bright's disease, is related to rapidly progressive glomerulonephritis and immune-complex glomerulonephritis. An important gene associated with Glomerulonephritis is CFHR5 (Complement Factor H Related 5), and among its related pathways/superpathways are Innate Immune System and Selenium Micronutrient Network. The drugs Angiotensin II and Losartan have been mentioned in the context of this disorder. Affiliated tissues include Kidney, kidney and neutrophil, and related phenotypes are Reduced mammosphere formation and cardiovascular system

Disease Ontology : 12 A nephritis that causes inflammation of the glomeruli located in kidney.

Wikipedia : 77 Glomerulonephritis (GN) is a term used to refer to several kidney diseases (usually affecting both... more...

Sources

Related Diseases for Glomerulonephritis

About this section

Diseases in the Glomerulonephritis family:

Autoimmune Glomerulonephritis Subacute Glomerulonephritis

Diseases related to Glomerulonephritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 741)
# Related Disease Score Top Affiliating Genes
1 rapidly progressive glomerulonephritis 34.3 MPO PRTN3 TGFB1
2 immune-complex glomerulonephritis 34.0 C4B CFI MPO
3 anti-basement membrane glomerulonephritis 33.9 COL4A3 COL4A5
4 dense deposit disease 33.8 C3 CFH CFHR5
5 proliferative glomerulonephritis 33.8 C3 CCL2 CFH CR1 MPO
6 acute proliferative glomerulonephritis 33.6 CCL2 COL4A3 MPO NPHS1
7 crescentic glomerulonephritis 33.5 CCL2 MPO NPHS2
8 complement factor h deficiency 33.5 CFH CFI
9 diffuse glomerulonephritis 33.5 ALB CFP
10 membranoproliferative glomerulonephritis 33.4 ALB C3 C4A CFH CFHR5 CFP
11 goodpasture syndrome 33.3 CFP COL4A3 COL4A5 MPO
12 c3 glomerulopathy 33.1 C3 CFHR5 CFP
13 iga glomerulonephritis 32.7 ALB CCL2 CFP NPHS1 NPHS2 TGFB1
14 membranous nephropathy 32.3 ALB C3 LRP2 MPO NPHS1 NPHS2
15 lipoid nephrosis 31.7 ALB CCL2 NPHS1 NPHS2
16 systemic lupus erythematosus 31.4 ALB C1QC C3 C4A C4B CCL2
17 vasculitis 31.3 CCL2 CFI MPO PRTN3
18 lupus erythematosus 31.2 C1QC C3 C4A C4B
19 hemolytic-uremic syndrome 30.8 C3 CFH CFHR5 CFI
20 anca-associated vasculitis 30.6 MPO PRTN3
21 subacute bacterial endocarditis 30.4 CFP MPO
22 nephrotic syndrome 30.4 ALB NPHS1 NPHS2
23 hemolytic uremic syndrome, atypical 1 30.2 C3 C4B CFH CFHR5 CFI CFP
24 focal segmental glomerulosclerosis 30.1 ALB COL4A3 COL4A5 NPHS1 NPHS2 TGFB1
25 complement deficiency 30.1 C3 C4A CFH CFP
26 meningitis 30.0 ALB CCL2 CFP
27 lung disease 30.0 CCL2 MPO PRTN3 TGFB1
28 complement component 3 deficiency 29.8 C3 CFI CFP
29 nephrotic syndrome, type 6 29.8 NPHS1 NPHS2
30 complement factor i deficiency 29.8 C3 C4B CFI CFP CR1
31 extrinsic allergic alveolitis 29.7 ALB CCL2 MPO
32 urinary tract obstruction 29.7 ALB CCL2 TGFB1
33 peritonitis 29.7 ALB CCL2 MPO
34 macular degeneration, age-related, 1 29.7 C3 CCL2 CFH CFHR5 CFI
35 afibrinogenemia 29.7 C3 CFI CFP CR1
36 hypersensitivity reaction type iii disease 29.5 ALB C3 C4A C4B MPO
37 end stage renal failure 29.4 ALB COL4A5 NPHS1 NPHS2 TGFB1
38 nephrosclerosis 29.4 CCL2 NPHS1 NPHS2 TGFB1
39 kidney disease 29.2 ALB C3 CCL2 CFH COL4A3 COL4A5
40 chronic kidney failure 29.2 ALB CFH COL4A5 NPHS1 NPHS2 TGFB1
41 diffuse mesangial sclerosis 28.9 NPHS1 NPHS2 TGFB1
42 mesangial proliferative glomerulonephritis 12.5
43 fibrillary glomerulonephritis 12.5
44 pauci-immune glomerulonephritis without anca 12.3
45 acute poststreptococcal glomerulonephritis 12.3
46 non-immunoglobulin-mediated membranoproliferative glomerulonephritis 12.2
47 membranoproliferative glomerulonephritis, x-linked 12.2
48 lipodystrophy, partial, acquired, with low complement component c3, with or without glomerulonephritis 12.2
49 pauci-immune glomerulonephritis 12.2
50 subacute glomerulonephritis 12.2

Graphical network of the top 20 diseases related to Glomerulonephritis:



Diseases related to Glomerulonephritis
Sources

Symptoms & Phenotypes for Glomerulonephritis

About this section

GenomeRNAi Phenotypes related to Glomerulonephritis according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.32 ALB C1QC C3 C4A CCL2 COL4A5

MGI Mouse Phenotypes related to Glomerulonephritis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.11 C3 C4B CFH CFP COL4A3 COL4A5
2 homeostasis/metabolism MP:0005376 10.1 ALB C3 C4B CFH CFI CFP
3 hematopoietic system MP:0005397 10.02 C3 C4B CFH CFI COL4A5 CSF1
4 immune system MP:0005387 9.93 C3 C4B CCL2 CFH CFP COL4A3
5 mortality/aging MP:0010768 9.77 ALB C3 C4B CFH CFP COL4A3
6 renal/urinary system MP:0005367 9.36 ALB C3 C4B CFH CFI COL4A3
Sources

Drugs & Therapeutics for Glomerulonephritis

About this section

Drugs for Glomerulonephritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 304)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198
2
Losartan Approved Phase 4,Phase 3,Phase 2,Not Applicable 114798-26-4 3961
3
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
4
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
5
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 302-25-0
6
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-24-8 5755
7
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 83-43-2 6741
8
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Not Applicable 2921-57-5
9
Benzocaine Approved, Investigational Phase 4,Phase 3,Not Applicable 1994-09-7, 94-09-7 2337
10
tannic acid Approved Phase 4,Phase 3,Not Applicable 1401-55-4
11
Enalaprilat Approved Phase 4,Phase 2,Not Applicable 76420-72-9 6917719
12
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 174722-31-7 10201696
13
Enalapril Approved, Vet_approved Phase 4,Phase 2,Not Applicable 75847-73-3 40466924 5362032
14
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 6473866 445643 439492
15
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 22916-47-8 4189
16
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 53-03-2 5865
17
Azathioprine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 446-86-6 2265
18
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
19
Ramipril Approved Phase 4,Phase 3 87333-19-5 5362129
20
Probucol Approved, Investigational Phase 4 23288-49-5 4912
21
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
22
Hydroxychloroquine Approved Phase 4 118-42-3 3652
23
Triamcinolone Approved, Vet_approved Phase 4,Phase 1,Not Applicable 124-94-7 31307
24
Bortezomib Approved, Investigational Phase 4 179324-69-7 387447 93860
25
Sirolimus Approved, Investigational Phase 4,Phase 2 53123-88-9 46835353 5284616 6436030
26
Everolimus Approved Phase 4,Phase 2 159351-69-6 70789204 6442177
27
Amoxicillin Approved, Vet_approved Phase 4,Not Applicable 26787-78-0 33613
28
Pentoxifylline Approved, Investigational Phase 4,Phase 3,Not Applicable 6493-05-6 4740
29
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
30
Artesunate Approved, Investigational Phase 4 88495-63-0 5464098 6917864
31
Basiliximab Approved, Investigational Phase 4,Phase 2 179045-86-4, 152923-56-3
32
Adenosine Approved, Investigational Phase 4 58-61-7 60961
33
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 7440-70-2 271
34
Calcitriol Approved, Nutraceutical Phase 4,Phase 2,Not Applicable 32222-06-3 5280453 134070
35
Serine Approved, Nutraceutical Phase 4,Phase 3,Not Applicable 56-45-1 5951
36
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Not Applicable 1406-16-2
37
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Not Applicable 50-14-6 5280793
38
N,N-dimethylarginine Experimental Phase 4 30315-93-6 123831
39
Cilnidipine Investigational Phase 4 132203-70-4 5282138
40
Candesartan Experimental Phase 4 139481-59-7 2541
41
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 2,Not Applicable 2920-86-7
42
Dexchlorpheniramine Experimental, Investigational Phase 4 25523-97-1 33036
43 Angiotensin Receptor Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
44 Angiotensin II Type 1 Receptor Blockers Phase 4,Phase 3,Phase 2,Not Applicable
45 Anti-Arrhythmia Agents Phase 4,Phase 3,Phase 2,Not Applicable
46 Angiotensinogen Phase 4,Phase 3,Phase 2,Not Applicable
47 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Not Applicable
48 Giapreza Phase 4,Phase 3,Phase 2,Not Applicable
49 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 403)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis Unknown status NCT02063100 Phase 4 Shenyankangfu tablets;Losartan potassium 50mg;Shenyankangfu tablets and Losartan potassium 50mg;Shenyankangfu tablets and Losartan potassium 100mg;Losartan potassium 100mg
2 Calcitriol in the Treatment of Immunoglobulin A Nephropathy Unknown status NCT00862693 Phase 4 Calcitriol
3 A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy Unknown status NCT01184599 Phase 4 aliskiren
4 CCB Safety Study in Treatment of Hypertension of ADPKD Unknown status NCT00541853 Phase 4 Candesartan;Candesartan and Cilnidipine;Candesartan plus non-CCB agents
5 Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid in Advanced IgA Nephropathy Unknown status NCT02981212 Phase 4 Mycophenolate Mofetil;ACE inhibitor;Corticosteroid;ARB
6 Rituximab in Recurrent IgA Nephropathy Unknown status NCT02571842 Phase 4 Intravenous Rituximab;ACEI/ARB and corticosteroids
7 Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy Unknown status NCT02231125 Phase 4 Losartan;Abelmoschus manihot
8 Mycophenolate Mofetil and Tacrolimus Versus Tacrolimus for the Treatment of Idiopathic Membranous Glomerulonephritis (IMG) Completed NCT00843856 Phase 4 tacrolimus;tacrolimus and mycophenolate mofetil
9 Inhibitors of Angiotensin II in Proteinuric Mesangioproliferative Glomerulonephritis Completed NCT01115426 Phase 4 Ramipril or losartan
10 HSP-glomerulonephritis Trial: MP vs CyA Completed NCT00425724 Phase 4 Methylprednisolone pulses plus prednisone versus Cyclosporine A
11 Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis Completed NCT01206569 Phase 4 Long-acting tacrolimus (Advagraf, Astellas Pharma)
12 Calcitriol in the Treatment of Immunoglobulin A (IgA) Nephropathy Completed NCT00319761 Phase 4 Calcitriol
13 A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy Completed NCT00426348 Phase 4 Valsartan;Probucol;Placebo
14 Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy: a Self- Controlled Study Completed NCT02351752 Phase 4 Hydroxychloroquine Sulfate
15 Mycophenolate Mofetil for IgA Nephropathy Completed NCT00863252 Phase 4 mycophenolate mofetil;angiotensin blockade
16 Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis Completed NCT00371319 Phase 4 tacrolimus;mycophenolate mofetil
17 Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects Completed NCT02585804 Phase 4 Dapagliflozin
18 Therapeutic Effect of Tacrolimus on Primary Nephrotic Syndrome in Children Completed NCT01162005 Phase 4 Tacrolimus
19 A Study to Evaluate the Effect of Tacrolimus and Corticosteroid Combination Therapy in Patients With Minimal Change Nephrotic Syndrome Completed NCT01763580 Phase 4 Tacrolimus;Prednisolone
20 The Effects of Angiotensin II Receptor Blockade on Kidney Function and Scarring After Liver Transplant Completed NCT00275639 Phase 4 Cozaar
21 Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis Completed NCT00125307 Phase 4 tacrolimus
22 Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade Completed NCT00922311 Phase 4 Aliskiren
23 "Steroids and Azathioprine Versus Steroids Alone in IgAN" Completed NCT00755859 Phase 4 steroids plus azathioprine;steroids
24 Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy Completed NCT00498368 Phase 4 Intravenous Rituximab;ACE/ARB
25 To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN) Completed NCT00518219 Phase 4 TW
26 Low-dose Combination of Mycophenolate Mofetil (MMF) and Tacrolimus (Tac) for Refractory Lupus Nephritis Completed NCT01203709 Phase 4 low dose combination of MMF and Tac
27 Pilot Study of Velcade® in IgA Nephropathy Completed NCT01103778 Phase 4 Bortezomib (Velcade®)
28 Inhibition of the Renin Angiotensin System Plus Corticosteroids for the Treatment of Proteinuria in IGA Nephropathy Completed NCT00367562 Phase 4 ENALAPRIL VALSARTAN METHYLPREDNISONE
29 Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients Completed NCT01386554 Phase 4 Repository Corticotropin Injection;Placebo
30 Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH Completed NCT01155141 Phase 4 H.P. Acthar Gel
31 SOCRATES: Steroid or Cyclosporine Removal After Transplantation Using Everolimus Completed NCT00371826 Phase 4 Everolimus (RAD001);Cyclosporine (Calcineurin Inhibitor (CNI));Methylprednisone/prednisone;Mycophenolate sodium (MPA)
32 Comparison of Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Lupus Nephritis Completed NCT02645565 Phase 4 Cyclophosphamide;Azathioprine;Methylprednisolone
33 Immunoadsorption in Anti-GBM Glomerulonephritis. Recruiting NCT02765789 Phase 4
34 Tacrolimus Combined With Entecavir on HBV Associated Glomerulonephritis(HBV-GN) Recruiting NCT03062813 Phase 4 Tacrolimus &entecavir;placebo & entecavir
35 Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy Recruiting NCT02765594 Phase 4 Hydroxychloroquine Sulfate;Valsartan
36 Adrenocorticotropic Hormone in Membranous Nephropathy Recruiting NCT03025828 Phase 4 ACTHar
37 Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy Recruiting NCT03170323 Phase 4 Mycophenolate Mofetil;Cyclosporins
38 Group A Pharyngitis in Children: The GASPARD Study Recruiting NCT03264911 Phase 4 Amoxicillin or Placebo
39 Fixed-dose Versus Concentration-controlled Mycophenolate Mofetil for the Treatment of Active Lupus Nephritis Recruiting NCT03920059 Phase 4 Mycophenolate Mofetil
40 Efficacy and Safety of Artesunate Plus Standard of Care in Active Lupus Nephritis Recruiting NCT03214731 Phase 4 Artesunate
41 Efficacy and Safety of Tacrolimus Versus Mycophenolate in Lupus Nephritis Recruiting NCT02630628 Phase 4 Tacrolimus;Mycophenolate mofetil
42 ACTHar in the Treatment of Lupus Nephritis Recruiting NCT02226341 Phase 4 CellCept;ACTHar gel;ACTHar gel
43 Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic FSGS Recruiting NCT02633046 Phase 4 Acthar 80 U 2x/week;Acthar 80 U 3x/week
44 Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment Active, not recruiting NCT02523768 Phase 4 ATG-F;Simulect
45 Extended Follow-up of Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy Active, not recruiting NCT03218852 Phase 4 prednisone and cyclophosphamide;prednisone alone
46 Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy Active, not recruiting NCT01758120 Phase 4 prednisone plus cyclophosphamide;Prednisone alone
47 Effect of Immunosuppression in IgA Nephropathy Not yet recruiting NCT03468972 Phase 4 Immunosuppressive treatment
48 Comparative Effectiveness of CEUS Versus DMSA in Renal Scarring Detection Not yet recruiting NCT03653702 Phase 4 Lumason
49 Pentoxifylline in Lupus Nephritis Not yet recruiting NCT03859570 Phase 4 Pentoxifylline;Placebos
50 Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease Terminated NCT01129557 Phase 4 Aliskiren;Valsartan

Search NIH Clinical Center for Glomerulonephritis

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Glomerulonephritis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Glomerulonephritis:
Mesenchymal stromal cells for glomerulonephritis
Embryonic/Adult Cultured Cells Related to Glomerulonephritis:
Bone marrow-derived mesenchymal stromal cells PMIDs: 22172807

Cochrane evidence based reviews: glomerulonephritis

Sources

Genetic Tests for Glomerulonephritis

About this section
Sources

Anatomical Context for Glomerulonephritis

About this section

MalaCards organs/tissues related to Glomerulonephritis:

42
Kidney, Neutrophil, T Cells, Liver, Lung, B Cells, Monocytes

The Foundational Model of Anatomy Ontology organs/tissues related to Glomerulonephritis:

20
Kidney
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Glomerulonephritis:
# Tissue Anatomical CompartmentCell Relevance
1 Kidney Glomerulus Affected by disease
Sources

Publications for Glomerulonephritis

About this section

Articles related to Glomerulonephritis:

(show top 50) (show all 6298)
# Title Authors Year
1
Plasma exchange is highly effective for ANCA-associated vasculitis patients with rapidly progressive glomerulonephritis who have advanced to dialysis dependence: A single-center case series. ( 31033151 )
2019
2
Role of regulatory T cells in experimental autoimmune glomerulonephritis. ( 30648909 )
2019
3
Dendritic cell-targeted CD40 DNA vaccine suppresses Th17 and ameliorates progression of experimental autoimmune glomerulonephritis. ( 30811635 )
2019
4
Anca negative pauci-immune crescentic glomerulonephritis and mixed connective tissue disease: a case study. ( 30897193 )
2019
5
OX40 ligand is inhibitory during the effector phase of crescentic glomerulonephritis. ( 29939347 )
2019
6
Antineutrophil cytoplasmic antibody and/or antiglomerular basement membrane antibody associated crescentic glomerulonephritis in combination with IgG4-related tubulointerstitial nephritis. ( 30183608 )
2019
7
Clinical outcomes in patients with biopsy-proved diabetic nephropathy compared to isolated lupus or crescentic glomerulonephritis. ( 30641169 )
2019
8
The co-inhibitory molecule PD-L1 contributes to regulatory T cell-mediated protection in murine crescentic glomerulonephritis. ( 30765734 )
2019
9
Plasmapheresis and corticosteroids in infective endocarditis-related crescentic glomerulonephritis. ( 30872338 )
2019
10
Role of CD8+ T cells in crescentic glomerulonephritis. ( 30879039 )
2019
11
Crescentic Glomerulonephritis and Membranous Nephropathy: An Unusual Association. ( 30983761 )
2019
12
Pauci-Immune Crescentic Glomerulonephritis due to Disseminated Histoplasmosis. ( 30993241 )
2019
13
Plasma exchange and rituximab treatments in primary membranous nephropathy combined with crescentic glomerulonephritis: A case report. ( 31045764 )
2019
14
Gremlin, A Potential Urinary Biomarker of Anca-Associated Crescentic Glomerulonephritis. ( 31053735 )
2019
15
Effectiveness of cryofiltration and mizoribine combination with oral steroid therapy in a patient with membranoproliferative glomerulonephritis due to essential cryoglobulinemia. ( 30927247 )
2019
16
Glomerulonephritis and nephrotic syndrome in a child with DiGeorge syndrome: Questions. ( 30963281 )
2019
17
Glomerulonephritis and nephrotic syndrome in a child with DiGeorge syndrome: Answers. ( 30963284 )
2019
18
Pauci-immune proliferative glomerulonephritis and fungal endocarditis: More than a mere coincidence? ( 30846459 )
2019
19
Cardiac Point-of-Care Ultrasound for the Diagnosis of Infective Endocarditis in a Patient with Non-Specific Rheumatologic Symptoms and Glomerulonephritis. ( 30996221 )
2019
20
Heavy Chain Fibrillary Glomerulonephritis: A Case Report. ( 30955945 )
2019
21
Elevated serum concentrations of DNAJB9 in fibrillary glomerulonephritis: another step toward understanding a progressive disease. ( 31010477 )
2019
22
Serum levels of DNAJB9 are elevated in fibrillary glomerulonephritis patients. ( 31010480 )
2019
23
Temporal change in life and renal prognosis of rapidly progressive glomerulonephritis in Japan via nationwide questionnaire survey. ( 30382510 )
2019
24
Exclusive expression of transmembrane TNF aggravates acute glomerulonephritis despite reduced leukocyte infiltration and inflammation. ( 30389199 )
2019
25
Treatment of recurrent, post-kidney transplant membranoproliferative glomerulonephritis with plasmapheresis and rituximab: A case report and literature review
. ( 30431428 )
2019
26
Infection-Related Glomerulonephritis. ( 30454751 )
2019
27
LncRNAs expression in adriamycin-induced rats reveals the potential role of LncRNAs contributing to chronic glomerulonephritis pathogenesis. ( 30458286 )
2019
28
Corticosteroid therapy alone for the treatment of C3 glomerulonephritis in association with monoclonal gammopathy
. ( 30474593 )
2019
29
How do lupus glomerulonephritis and its treatment affect the renal reserve? ( 30515736 )
2019
30
IgA-proliferative glomerulonephritis with monoclonal immunoglobulin deposits. ( 30611830 )
2019
31
Small Red Blood Cell Fraction on the UF-1000i Urine Analyzer as a Screening Tool to Detect Dysmorphic Red Blood Cells for Diagnosing Glomerulonephritis. ( 30623619 )
2019
32
Successful entecavir plus prednisolone treatment for hepatitis B virus-associated membranoproliferative glomerulonephritis: A case report. ( 30633192 )
2019
33
Pneumonia-Associated Acute Glomerulonephritis: Report of 2 Cases. ( 30658555 )
2019
34
TRPC6 inactivation does not affect loss of renal function in nephrotoxic serum glomerulonephritis in rats, but reduces severity of glomerular lesions. ( 30662960 )
2019
35
Changes in primary glomerulonephritis in Singapore over four decades
. ( 30663975 )
2019
36
Proliferative glomerulonephritis with monoclonal Ig deposits (PGNMID): diagnostic and treatment challenges for the nephrologist! ( 30665574 )
2019
37
Acute IgA-Dominant Glomerulonephritis Associated with Syphilis Infection in a Pregnant Teenager: A New Disease Association. ( 30669309 )
2019
38
Development of anti-glomerular basement membrane glomerulonephritis during the course of IgA nephropathy: a case report. ( 30683055 )
2019
39
Reversible SAHH inhibitor protects against glomerulonephritis in lupus-prone mice by downregulating renal α-actinin-4 expression and stabilizing integrin-cytoskeleton linkage. ( 30696480 )
2019
40
Endogenous IL-22 is dispensable for experimental glomerulonephritis. ( 30724106 )
2019
41
Distinction between MPO-ANCA and PR3-ANCA-associated glomerulonephritis in Chinese patients: a retrospective single-center study. ( 30737591 )
2019
42
Comparing outcomes of biopsy-proven anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis patients treated with cyclophosphamide in the 20th and 21st centuries: a 23-year study. ( 30746129 )
2019
43
Recurrent proliferative glomerulonephritis with monoclonal immunoglobulin deposits in kidney allografts treated with anti-cd20 antibodies. ( 30747850 )
2019
44
Dual anti-neutrophil cytoplasmic antibody and anti-glomerular basement membrane antibody-positive crescent glomerulonephritis in a patient with monoclonal gammopathy of undetermined significance: A case report. ( 30762802 )
2019
45
Complete biopsy-proven resolution of deposits in recurrent proliferative glomerulonephritis with monoclonal IgG deposits (PGNMIGD) following rituximab treatment in renal allograft. ( 30764798 )
2019
46
Immune Check Point Inhibitor-Associated Glomerulonephritis. ( 30775635 )
2019
47
Visceral Leishmaniasis and Glomerulonephritis: A Case Report. ( 30787856 )
2019
48
NPHS2 gene sequencing results in children of the Azerbaijani population with different types of nephrotic syndrome caused by chronic glomerulonephritis. ( 30793612 )
2019
49
IgA dominant postinfectious glomerulonephritis secondary to cutaneous infection by methicillin-resistant Staphylococcus aureus. ( 30798997 )
2019
50
Widening spectrum of renal involvement in psoriasis: First reported case of C3 glomerulonephritis in a psoriatic patient. ( 30804292 )
2019
Sources

Variations for Glomerulonephritis

About this section

ClinVar genetic disease variations for Glomerulonephritis:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 CEL NM_001807.4(CEL): c.1975G> C (p.Ala659Pro) single nucleotide variant Uncertain significance rs587780309 GRCh37 Chromosome 9, 135946855: 135946855
2 CEL NM_001807.4(CEL): c.1975G> C (p.Ala659Pro) single nucleotide variant Uncertain significance rs587780309 GRCh38 Chromosome 9, 133071468: 133071468

Copy number variations for Glomerulonephritis from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 21052 1 156500000 165500000 Copy number FCGR3 Glomerulonephritis
2 21055 1 156500000 165500000 Loss FCGR3B Glomerulonephritis
3 21056 1 156500000 165500000 Low copy number FCGR3B Glomerulonephritis
Sources

Expression for Glomerulonephritis

About this section
Search GEO for disease gene expression data for Glomerulonephritis.
Sources

Pathways for Glomerulonephritis

About this section

Pathways related to Glomerulonephritis according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 67
Show member pathways
 13.88 C1QC C3 C4A C4B CCL2 CFH
2
Selenium Micronutrient Network 1
Show member pathways
 12.19 ALB CCL2 CSF1 LRP2 MPO
3
Creation of C4 and C2 activators 67
Show member pathways
 12.03 C1QC C3 C4A C4B CFH CFI
4
Complement and coagulation cascades 1 38
11.94 C1QC C3 C4A C4B CFH CFI
5
AGE-RAGE signaling pathway in diabetic complications 38
11.8 CCL2 COL4A3 COL4A5 TGFB1
6
Amoebiasis 38
11.72 COL4A3 COL4A5 TGFB1
7
Primary Focal Segmental Glomerulosclerosis FSGS 1
11.71 COL4A3 COL4A5 CR1 NPHS1 NPHS2 TGFB1
8
Rheumatoid arthritis 38
11.67 CCL2 CSF1 TGFB1
9
Pertussis 38
11.61 C1QC C3 C4A C4B
10
Complement Pathway 65
Show member pathways
 11.53 C1QC C3 C4A C4B CFH CFP
11
Staphylococcus aureus infection 38
11.47 C1QC C3 C4A C4B CFH CFI
12
Cell adhesion_Plasmin signaling 23
11.39 COL4A3 COL4A5 TGFB1
13
Malaria 38
11.38 CCL2 CR1 TGFB1
14
Immune response Lectin induced complement pathway 23
Show member pathways
 11.35 C1QC C3 C4A C4B CFH CFI
15
G-protein signaling_Rap2B regulation pathway 23
10.85 CCL2 COL4A3 COL4A5 CSF1 TGFB1
16
LDL Oxidation in Atherogenesis 65
10.78 CCL2 CSF1 MPO
Sources

GO Terms for Glomerulonephritis

About this section

Cellular components related to Glomerulonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.86 ALB C1QC C3 C4A C4B CCL2
2 collagen-containing extracellular matrix GO:0062023 9.85 C1QC CFP COL4A3 COL4A5 PRTN3 TGFB1
3 endoplasmic reticulum lumen GO:0005788 9.8 ALB C3 C4A CFP COL4A3 COL4A5
4 blood microparticle GO:0072562 9.7 ALB C1QC C3 C4A C4B CFH
5 azurophil granule lumen GO:0035578 9.65 C3 MPO PRTN3
6 collagen trimer GO:0005581 9.63 C1QC COL4A3 COL4A5
7 extracellular space GO:0005615 9.5 ALB C1QC C3 C4A C4B CCL2
8 slit diaphragm GO:0036057 9.43 NPHS1 NPHS2
9 collagen type IV trimer GO:0005587 9.4 COL4A3 COL4A5
10 extracellular exosome GO:0070062 10.1 ALB C3 C4A C4B CFH CFI

Biological processes related to Glomerulonephritis according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.97 C3 C4A C4B CR1 CSF1
2 neutrophil degranulation GO:0043312 9.91 C3 CFP CR1 MPO PRTN3
3 inflammatory response GO:0006954 9.88 C3 C4A C4B CCL2 CSF1 TGFB1
4 cytokine-mediated signaling pathway GO:0019221 9.85 CCL2 CSF1 PRTN3 TGFB1
5 complement activation, classical pathway GO:0006958 9.85 C1QC C3 C4A C4B CFI CR1
6 innate immune response GO:0045087 9.81 C1QC C3 C4A C4B CFH CFI
7 cellular protein metabolic process GO:0044267 9.78 ALB C3 C4A CSF1
8 negative regulation of endopeptidase activity GO:0010951 9.76 C3 C4A C4B COL4A3
9 complement activation GO:0006956 9.73 C1QC C3 C4A C4B CFH CFP
10 complement activation, alternative pathway GO:0006957 9.62 C3 CFH CFHR5 CFP
11 positive regulation of cellular protein metabolic process GO:0032270 9.58 CSF1 TGFB1
12 regulation of regulatory T cell differentiation GO:0045589 9.56 CR1 TGFB1
13 negative regulation of phagocytosis GO:0050765 9.54 PRTN3 TGFB1
14 collagen-activated tyrosine kinase receptor signaling pathway GO:0038063 9.52 COL4A3 COL4A5
15 glomerular basement membrane development GO:0032836 9.49 COL4A3 NPHS1
16 proteolysis GO:0006508 9.43 CFI PRTN3
17 regulation of complement activation GO:0030449 9.28 C1QC C3 C4A C4B CFH CFHR5
18 positive regulation of apoptotic cell clearance GO:2000427 9.26 C3 C4A C4B CCL2

Molecular functions related to Glomerulonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endopeptidase inhibitor activity GO:0004866 9.13 C3 C4A C4B
2 serine-type endopeptidase activity GO:0004252 8.62 CFI PRTN3
Sources

Sources for Glomerulonephritis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....